Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/09/26	€0.0460	0.00%	0
28/09/26	€0.0460	0.00%	330
25/09/26	€0.0460	0.00%	0
24/09/26	€0.0460	0.00%	0
23/09/26	€0.0460	0.00%	0

End-of-day quote Deutsche Boerse AG

More quotes

End-of-day quote Deutsche Boerse AG 29/09/2026			5-day change	1st Jan Change
0.0460 ^EUR	0.00%		0.00%	+248.48%

Market Cap	144K 163K 136K 124K 232K 15.67M 234K 1.64M 630K 8M 613K 600K 25.75M	P/E 2021	-3.89x	P/E 2022	-53x
Enterprise Value	9.87M 11.18M 9.34M 8.47M 15.87M 1.07B 16.03M 112M 43.16M 548M 41.98M 41.07M 1.76B	EV / Sales 2021	14.1x	EV / Sales 2022	1.22x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

Markets		Quality
Deutsche Boerse AG	PA8K	End-of-day quote
Tradegate	PA8	Real-time
OTC Markets	PAIOF	Delayed
Deutsche Boerse AG	PA8	Delayed
Börse Stuttgart	PA8	Delayed
Boerse Muenchen	PA8	Real-time

1 month	-8.00%
3 months	-14.81%
6 months	+41.98%
Current year	+248.48%

1 week	0.05	0.05
1 month	0.05	0.05
Current year	0.01	0.23
1 year	0.01	0.23
3 years	0	4.32
5 years	0	18.94
10 years	0	36.78

Paion AG Stock

Stocks

PA8K

DE000A3E5EG5

Biotechnology & Medical Research

Valuation: Paion AG

Chart: Paion AG

Latest news: Paion AG

Press Releases: Paion AG

News in other languages: Paion AG

Quotes and Performance

Price Extremes

Managers and Directors: Paion AG

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Tilmann Bur CEO	Chief Executive Officer	62	01/09/2023
Sebastian Werner DFI	Director of Finance/CFO	-	01/06/2022

Director	Title	Age	Since
Karin Louise Dorrepaal BRD	Director/Board Member	65	01/10/2012
Hans Tanner BRD	Director/Board Member	75	01/06/2017
Markus Guilherme Dieken BRD	Director/Board Member	-	22/05/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/27/22 A	Gregor Siebert	Buy	Director	1,121	0.0016%
1/12/21 A	James Phillips	Buy	Chief Executive Officer	8,500	0.0127%
6/8/20 A	James Phillips	Buy	Chief Executive Officer	13,158	0.0202%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PAION AG	0.00%	0.00%	+350.98%	-98.77%	372K
LONZA GROUP AG	-0.03%	+3.77%	+12.35%	+37.22%	48.85B
IQVIA HOLDINGS INC.	-0.73%	-0.41%	+48.84%	+36.72%	44.28B
REVOLUTION MEDICINES, INC.	+1.36%	+6.03%	+343.85%	+638.73%	43.83B
BEONE MEDICINES AG	-0.47%	-0.76%	+9.75%	+103.07%	41.53B
CELLTRION, INC.	+0.34%	+0.22%	+5.18%	+47.36%	30.13B
MEDPACE HOLDINGS, INC.	+1.00%	-1.28%	+24.23%	+156.93%	17.36B
EUROFINS SCIENTIFIC SE	-3.20%	-3.50%	+25.33%	+42.43%	14.99B
TEMPUS AI, INC.	-2.94%	+6.98%	+5.10%	-	14.9B
ASCENDIS PHARMA A/S	-0.86%	-4.00%	-	-	14.98B
Average	-0.55%	+0.55%	+91.73%	+120.46%	27.08B
Weighted average by Cap.	-0.26%	+1.21%	+75.32%	+168.10%

	2021	2022
Net sales	7.13M 8.08M 6.74M 6.12M 11.47M 775M 11.58M 80.91M 31.18M 396M 30.33M 29.67M 1.27B	33.25M 37.67M 31.46M 28.53M 53.49M 3.62B 54.01M 377M 145M 1.85B 141M 138M 5.94B
Net income	-21.79M -24.69M -20.61M -18.69M -35.05M -2.37B -35.39M -247M -95.3M -1.21B -92.7M -90.68M -3.89B	-579K -656K -548K -497K -931K -62.96M -941K -6.57M -2.53M -32.15M -2.46M -2.41M -103M
Net Debt	13.77M 15.6M 13.03M 11.81M 22.15M 1.5B 22.37M 156M 60.23M 765M 58.59M 57.31M 2.46B	9.72M 11.02M 9.2M 8.34M 15.64M 1.06B 15.8M 110M 42.53M 540M 41.37M 40.47M 1.74B